US Stock MarketDetailed Quotes

BEAM Beam Therapeutics

Watchlist
  • 26.620
  • +2.690+11.24%
Close Nov 6 16:00 ET
  • 26.120
  • -0.500-1.88%
Post 17:25 ET
2.20BMarket Cap-16848P/E (TTM)

About Beam Therapeutics Company

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Company Profile

SymbolBEAM
Company NameBeam Therapeutics
Listing DateFeb 6, 2020
Issue Price17.00
Founded2017
CEOMr. John Evans
MarketNASDAQ
Employees436
Fiscal Year Ends12-31
Address238 Main Street,9th floor
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142-1016
Phone1-857-327-8775
Websitehttp://www.beamtx.com

Company Executives

  • Name
  • Position
  • Salary
  • John Evans
  • Chief Executive Officer, Principal Financial and Accounting Officer and Director
  • 6.28M
  • Dr. Amy Simon, M.D.
  • Chief Medical Officer
  • 2.55M
  • Dr. Christine Bellon, PhD
  • Chief Legal Officer and Secretary
  • 2.28M
  • Dr. Giuseppe Ciaramella, PhD
  • President
  • 2.79M
  • Kathleen E. Walsh
  • Independent Director
  • 447.72K
  • Dr. Mark C. Fishman, M.D.
  • Lead Independent Director
  • 465.22K
  • Christi Shaw
  • Independent Director
  • 772.68K
  • Graham K. Cooper
  • Independent Director
  • 450.22K
  • Dr. John M. Maraganore,PhD
  • Independent Director
  • 435.22K
  • Dr. Carole Ho, M.D.
  • Independent Director
  • 442.72K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Concept ARK Portfolio
ARK Portfolio
Intraday+12.68%
Gene Editing
Gene Editing
Intraday-1.02%